Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Alosetron is a 5-HT3 antagonist used for the treatment of irritable bowel syndrome (IBS) with predominantly severe diarrhea in women. Oral administration twice daily.
At the time of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (very large volume of distribution and mode high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.
Its low oral bioavailability (even lower if taken with food) makes it difficult to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period where there may be greater intestinal permeability.
Possible exposure can be decreased by waiting 3 hours after taking the drug to resume breastfeeding.